Immuno-oncology (IO) therapy is a new (and old) way to treat cancer by activating your immune system in the hope that it will attack your tumour. Our sister site ‘10-for-IO’ is a central resource for patient organisations to access information about immuno-oncology specifically as it applies to renal cell carcinoma. Click here for more information.
Cancer is one of the world’s most pressing health care challenges. On the whole, research progress from one year to the next is incremental, and true breakthroughs are exceptional. Nevertheless, every year brings new knowledge and insights that help direct further research and ultimately improve the outlook for patients with cancer. Clinical Cancer Advances 2017 highlights the most important clinical advances of the past year and previews where cancer science is headed. Advances highlighted
The KCSN Patient Champion Programmed works to build awareness of clinical trials and encourage patients to consider participation.
Dr. Laurence Albiges, Oncologist, head of the GU Tumor Board at the Gustave Roussy speaking during ESMO 2016 about how immunotherapy has had an impact on the field of renal cell carcinoma (RCC). Watch the video.
Dose escalation of tyrosine kinase inhibitors (TKIs) after disease progression in patients with metastatic renal cell carcinoma (mRCC) can lead to a decrease in tumour burden and extend duration of therapy, according to a study. Read more
The European Medicines Agency (EMA) has approved Cabozantinib as a second-line treatment option for patients with advanced renal cell carcinoma (RCC) who have previously been treated with vascular endothelial growth factor (VEGF)-targeted therapy. Read more.